Pharma Bio Serv Stock Performance
| PBSV Stock | USD 0.50 0.05 9.09% |
The company holds a Beta of -0.98, which implies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Pharma Bio are expected to decrease slowly. On the other hand, during market turmoil, Pharma Bio is expected to outperform it slightly. At this point, Pharma Bio Serv has a negative expected return of -0.18%. Please make sure to check Pharma Bio's total risk alpha, as well as the relationship between the daily balance of power and relative strength index , to decide if Pharma Bio Serv performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Pharma Bio Serv has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors. ...more
| Begin Period Cash Flow | 17.5 M | |
| Free Cash Flow | 573.2 K |
Pharma |
Pharma Bio Relative Risk vs. Return Landscape
If you would invest 63.00 in Pharma Bio Serv on September 12, 2024 and sell it today you would lose (13.00) from holding Pharma Bio Serv or give up 20.63% of portfolio value over 90 days. Pharma Bio Serv is currently does not generate positive expected returns and assumes 6.1461% risk (volatility on return distribution) over the 90 days horizon. In different words, 54% of otc stocks are less volatile than Pharma, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Pharma Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Pharma Bio's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Pharma Bio Serv, and traders can use it to determine the average amount a Pharma Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0301
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PBSV |
Estimated Market Risk
| 6.15 actual daily | 54 54% of assets are less volatile |
Expected Return
| -0.18 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.03 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Pharma Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Pharma Bio by adding Pharma Bio to a well-diversified portfolio.
Pharma Bio Fundamentals Growth
Pharma OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Pharma Bio, and Pharma Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Pharma OTC Stock performance.
| Return On Equity | 0.0568 | |||
| Return On Asset | 0.033 | |||
| Profit Margin | 0.05 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 4.87 M | |||
| Shares Outstanding | 22.95 M | |||
| Price To Earning | 10.00 X | |||
| Price To Book | 1.15 X | |||
| Price To Sales | 0.90 X | |||
| Revenue | 19.4 M | |||
| EBITDA | 1.23 M | |||
| Cash And Equivalents | 14.24 M | |||
| Cash Per Share | 0.62 X | |||
| Total Debt | 520.77 K | |||
| Debt To Equity | 0.03 % | |||
| Book Value Per Share | 0.72 X | |||
| Cash Flow From Operations | 592.46 K | |||
| Earnings Per Share | 0.04 X | |||
| Total Asset | 20.65 M | |||
| Retained Earnings | 20.5 M | |||
| Current Asset | 22.27 M | |||
| Current Liabilities | 1.67 M | |||
About Pharma Bio Performance
Evaluating Pharma Bio's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Pharma Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Pharma Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Pharma-Bio Serv, Inc. operates as a compliance and technology transfer services consulting firm. The company was founded in 1993 and is headquartered in Dorado, Puerto Rico. Pharma Bio operates under Health Information Services classification in the United States and is traded on OTC Exchange. It employs 190 people.Things to note about Pharma Bio Serv performance evaluation
Checking the ongoing alerts about Pharma Bio for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Pharma Bio Serv help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Pharma Bio Serv generated a negative expected return over the last 90 days | |
| Pharma Bio Serv has high historical volatility and very poor performance | |
| Pharma Bio Serv has some characteristics of a very speculative penny stock | |
| About 65.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Pharma Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Pharma Bio's stock is overvalued or undervalued compared to its peers.
- Examining Pharma Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Pharma Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Pharma Bio's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Pharma Bio's otc stock. These opinions can provide insight into Pharma Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Pharma OTC Stock Analysis
When running Pharma Bio's price analysis, check to measure Pharma Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharma Bio is operating at the current time. Most of Pharma Bio's value examination focuses on studying past and present price action to predict the probability of Pharma Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharma Bio's price. Additionally, you may evaluate how the addition of Pharma Bio to your portfolios can decrease your overall portfolio volatility.